Lipocine Inc. (LPCN)
| Market Cap | 104.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.75M |
| Shares Out | 64.83M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.62 |
| Previous Close | $1.65 |
| Change ($) | -0.03 |
| Change (%) | -1.82% |
| Day's Open | 1.67 |
| Day's Range | 1.56 - 1.68 |
| Day's Volume | 1,822,127 |
| 52-Week Range | 0.32 - 2.23 |
Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Pa...
SALT LAKE CITY, Dec. 30, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is ...
SALT LAKE CITY, Dec. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge ...
Lipocine: Imminent Catalysts In NASH And Oral Testosterone Replacement Therapy Make For A Strong Buy
LPCN's long road to market for its oral testosterone pill has been bumpy; however, the FDA just gave TLANDO tentative approval.
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S...
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an inde...
SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S...
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete ...
Lipocine is about to report data from its clinical study on whether TLANDO can restore testosterone levels in hypogonadal men without the dose titration requirement on November 9, 2020. Low ba...
SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S...
SALT LAKE CITY, Aug. 28, 2020 /PRNewswire/ -- Lipocine Inc.
SALT LAKE CITY, Aug. 6, 2020 /PRNewswire/ -- Lipocine Inc.
SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Lipocine Inc.
SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has...
SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinica...
Lipocine Inc. (NASDAQ: LPCN) shares absolutely plummeted on Monday after the firm announced that it received a Complete Response Letter (CRL) from the U.S.
Lipocine Inc (NASDAQ: LPCN) shares are tumbling to record lows after an adverse FDA verdict on its lead drug Tlando, previously known as LPCN 1021.
Shares of Lipocine Inc. LPCN, -2.50% plummeted 67% toward a record low, and to pace all premarket losers, after the biopharmaceutical company said the Food and Drug Administration indicated th...
Lipocine Inc is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate.
About LPCN
Lipocine, a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. I... [Read more...]
| Industry Biotechnology | |
| CEO Mahesh Patel | Employees 12 |
| Stock Exchange NASDAQ | Ticker Symbol LPCN |
Financial Performance
In 2019, Lipocine's revenue was $164,990, a decrease of -61.45% compared to the previous year's $428,031. Losses were -$13.01 million, 11.6% more than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for Lipocine stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 229.01% from the latest price.